News for Dynavax Technologies Corporation (DVAX)

Deep Track Capital, LP, (together with its affiliates, ”œDeep Track” or ”œwe”), one of the largest shareholders of Dynavax Technologies Corporation (NASD

Dynavax Technologies Corporation sees strong Q4 results, with Heplisav-B boosting revenue. Click for my updated look at DVAX and a look ahead.

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look at where Dynavax Technologies Corporation (NASDAQ:DVAX) stands against the ...

PR NewswireEMERYVILLE, Calif., Feb. 25, 2025 EMERYVILLE, Calif., Feb. 25, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercia

The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 81.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ETCompany ParticipantsPaul Cox - Vice President,...

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 25% and 0.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

The following slide deck was published by Dynavax Technologies Corporation in conjunction with their 2024 Q4 earnings call.

Learn about Deep Track Capital's proxy fight with Dynavax (DVAX) and their push to prioritize Heplisav's growth.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

PR NewswireEMERYVILLE, Calif., Feb. 6, 2025 EMERYVILLE, Calif., Feb. 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial

The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 93.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

PR NewswireEMERYVILLE, Calif., Jan. 27, 2025 Appoints Emilio Emini and Lauren Silvernail to Board of Directors; Two Directors to Step Down at 2025 Annual M

Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Analysis of HEPLISAV-B® net product revenue growth in 2024, showing a 26% increase to $268 million, reflecting positive financial performance.

Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.

Data demonstrate superiority of HepB-CpG vaccination over conventional hepatitis B vaccines among people living with HIV

The average of price targets set by Wall Street analysts indicates a potential upside of 93.5% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

PR NewswireEMERYVILLE, Calif., Nov. 26, 2024 EMERYVILLE, Calif., Nov. 26, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercia